Related Experiment Video

Updated: Mar 27, 2026

Mechanisms Underlying Gut Hormone Secretion Using the Isolated Perfused Rat Small Intestine
07:00

Mechanisms Underlying Gut Hormone Secretion Using the Isolated Perfused Rat Small Intestine

Published on: February 26, 2019

10.1K

Mechanisms of GLP-1 Receptor Agonists in HFpEF: Exploring Weight-Dependent and Independent Drivers of Therapeutic

Jordyn Thomas1, Misha Dagan1,2,3, Bing Wang1,3

  • 1Heart Failure Research Group, Baker Heart and Diabetes Institute, Melbourne, VIC, Australia (J.T., M.D., B.W., S.G., D.M.K.).

Circulation. Heart Failure
|March 25, 2026
PubMed

Insights

Glucagon-like peptide-1 receptor agonists (GLP-1RAs) show promise for heart failure with preserved ejection fraction (HFpEF), especially in obese patients. These agents improve symptoms and reduce events through weight loss and direct cardiovascular benefits.

Area of Science:

  • Cardiology
  • Metabolic Disorders
  • Pharmacology

Background:

  • Heart failure with preserved ejection fraction (HFpEF) is a growing clinical challenge, frequently linked to obesity, diabetes, and hypertension.
  • Therapeutic options for HFpEF remain limited compared to heart failure with reduced ejection fraction.
  • Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are emerging as a novel treatment strategy for HFpEF, particularly in patients with metabolic comorbidities.

Purpose of the Study:

  • To review the multifaceted mechanisms of GLP-1RAs in HFpEF.
  • To explore both weight-dependent and weight-independent effects of GLP-1RAs.
  • To elucidate how GLP-1RAs impact cardiovascular physiology and related pathways in HFpEF.

Main Methods:

  • Review of recent clinical trial data (e.g., STEP-HFpEF, SUMMIT).
  • Synthesis of evidence on the physiological effects of GLP-1RAs.
  • Analysis of weight-dependent and independent actions relevant to HFpEF.

Main Results:

  • GLP-1RAs have demonstrated significant improvements in HFpEF symptoms and quality of life.
  • Trials show reductions in heart failure events with GLP-1RA use.
  • Beyond weight loss, GLP-1RAs exhibit metabolic, cardiovascular, and anti-inflammatory effects.

Conclusions:

  • GLP-1RAs represent a promising therapeutic avenue for HFpEF, particularly the obese/cardiometabolic phenotype.
  • Their benefits stem from substantial weight reduction and direct cardioprotective actions.
  • Further understanding of GLP-1RA mechanisms can optimize HFpEF management.

Keywords:
GLP1 receptor agonistsheart failure with preserved ejection fractionobesity

More Related Videos

Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction09:20

Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction

Published on: February 13, 2021

7.2K
Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF03:42

Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF

Published on: March 29, 2024

2.2K

Related Concept Videos

Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
1.3K
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
4.8K
GPCRs Regulate Adenylyl Cylase Activity01:09

GPCRs Regulate Adenylyl Cylase Activity

Some GPCRs transmit signals through adenylyl cyclase (AC), a transmembrane enzyme. AC helps synthesize second messenger cyclic adenosine monophosphate (cAMP). AC catalyzes cyclization reaction and converts ATP to cAMP by releasing a pyrophosphate. The pyrophosphate is further hydrolyzed to phosphate by the enzyme pyrophosphatase, which drives cAMP synthesis to completion. However, cAMP is rapidly degraded to 5′ AMP by the enzymes phosphodiesterase (PDE), preventing overstimulation of...
8.2K
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
517
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
1.0K
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
597